A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients

A 2-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Tolerability and Pharmacokinetics of Orally Administered AZD9668 in Patients With COPD

The purpose of this study is to assess the tolerability (effect of drug on body) and pharmacokinetics (effect of body on drug) of AZD9668 in patients with mild to moderate COPD

Inclusion Criteria:

• Mild to moderate COPD
• Smokers or ex-smokers
• post-menopausal females

Exclusion Criteria:

• Past history or current evidence of clinically significant heart disease
• Lung disease other than COPD
• Treatment with systemic steroids within 8 weeks of study visit 2
• Treatment with antibiotics within 4 weeks of study visit 1 or study visit 2